Long COVID or Post-acute sequelae of COVID-19 (PASC) can affect up to 15% of COVID-19 survivors. The most common symptoms of long covid include fatigue (84%) body aches (46%), loss of taste and/or smell (46%), anxiety (31%), shortness of breath (31%), brain fog (23%) and/or headaches (23%).
There are 5 main proposed mechanisms that may cause persistent inflammation leading to long COVID. These include:
- reactivation of latent viruses
- coronavirus 2 viral persistence
- loss of immunoregulatory pathways
- autoimmune mechansisms
- mast cell dysregulation
Evaluation of patients with long COVID include general screening laboratory and inflammatory biomarkers and may also include more specific workup on a case by case basis depending on the symptoms. Recommended baseline tests include CBC, renal function tests, liver function tests, C-reactive protein, thyroid function, hemoglobin A1c, vitamin D, magnesium, B12, folate, and ferritin levels. More advanced testings can include, D-dimer, ESR, IL-6 and procalcitonin.
Persistent inflammation can also be a result from elevated IgG and IgM antibodies to EBV, HHV-6 and CMV among others.
Other autoimmune diseases that may develop are systemic lupus erythematous, type 1 diabetes mellitus, immune thrombocytopenia purpura, autoimmune thyroid disease and Guillain-Barre syndrome. Several autoantibodies found include antinuclear antibodies, antineutrophilic cytoplasmic antibody, and other antibodies against cutaneous antigens.
Complement activation has found be dysregulated in COVID-19, although measuring complement levels is unclear in assessing long COVID.
Mast cell activation syndrome has been associated with PASC. The diagnosis of MCAS is made when the following criteria are fulfilled.
- typical clinical signs and symptoms of MCAS
- evidence of mast cell mediator release. Objective evidence of mast cell activation is revealed by an elevation of serum tryptase to (1.2 x baseline) / 2 ng/ml above baseline during an acute flare. This can be revealed by exhibiting elevated levels of N-methylhistamine or leukotriene E4 on a 24 hour urine sample.
- symptoms respond to medications that stabilize mast cells or block the activation of mast cell mediators.
There are no approved or even proven therapies for long COVID, a variety of therapeutic options have been identified that either may reduce the risk of progression to PASC or decrease symptom burden.
One review suggested that receiving 2-3 doses of the vaccine can reduce the risk of developing PASC, but receiving the vaccine during long COVID can prolong the symptoms.
The use of antiviral medication nirmatrelvir-ritonavir has revealed efficacy in the treatment of acute COVID-19. There are ongoing clinical trials for long COVID.
Montelukast (Singulair) may have a therapeutic value in long COVID. Typical treatment of MCAS, include high dose H1 and H2 antihistamines, singulair and mast cell stabilizers such as cromolyn. There are mixed opinions on the role of oral prednisone on the use for PASC.
Other treatments being used or studied include, Vitamin D, Metformin, Ivermectin, Fluvoxamine, Sodium Pyruvate Nasal spray, ultramicronized Palmitoylethanolamide and Luteolin. IVIG has been used, and clinic trials are in progress.
There are more than 400 ongoing clinical trials in evaluating patients with long COVID. There is no blanket approach and a more refined definition of PASC is needed to address the wide variety of clinical presentations, pathophysiology and therapeutic options.
Mast Cell Activation Syndrome (MCAS): Fact & Fiction
Can the Covid Vaccine cause Hives?
Covid with Xolair, Nucala, Cinqair, Fasenra or Dupixent for Asthma
